Skip to content

Released Mar 8, 2016, after the close

10-K filed Mar 8, 2016, 68 days after period end · 0001144204-16-086642

Q4 2015 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$0.00derivedno prior Q4 2014 on file−100.0% vs Q3 2015
Net Income$72.90MderivedN/M vs Q4 2014N/M vs Q3 2015
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$0N/M
Operating Incomederived-$7,700,000N/M
Operating Cash Flowderived-$3,857,000N/M
Free Cash Flowderived-$3,861,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2015derived from reported figuresQ4 2014derived from reported figuresQ4 2013derived from reported figuresQ4 2012derived from reported figures
Revenue$0.00——$1.17M
Net Income$72.90M-$8.47M-$10.89M-$9.88M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR